Iovance Biotherapeutics, Inc.
Moat Score — Iovance Biotherapeutics, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Iovance holds over 330 granted or allowed patents and applications, including more than 90 US TIL-specific patents, with AMTAGVI exclusivity expected into 2042, giving it a strong and lengthy legal moat around the first approved TIL therapy for a solid tumor. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | The in-house iCTC manufacturing transition is designed to improve gross margin versus prior contract manufacturing, but as a newly scaling, capital-intensive cell-therapy process, it does not yet represent a proven structural cost advantage over future competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the sole approved individualized TIL therapy for previously treated advanced melanoma, AMTAGVI has meaningful first-in-class pricing power, tempered by the need for payor acceptance of a novel, high-cost cell therapy and reliance on specialized authorized treatment centers. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | TIL cell therapy exhibits no network effect; each patient's individualized treatment and outcome is independent of how many other patients have been treated. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a treatment center becomes an authorized AMTAGVI site and establishes the operational workflow for TIL therapy, there is some institutional switching friction, but this reflects onboarding investment rather than a durable lock-in versus a future competing cell therapy. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The iCTC's first-mover, FDA-approved commercial-scale TIL manufacturing capacity (5,000+ patients/year potential) is a genuine operational barrier that newer entrants would need years to replicate, though the overall solid-tumor cell therapy market remains young enough that this advantage is not yet fully proven against future competitors. |